Honors & Awards

  • Scholarship for extraordinary Attainment, Konrad-Adenauer Foundation (06/2002 - 11/2006)
  • Postdoctoral Fellowship, Will Foundation (10/2012 - 09/2013)

Boards, Advisory Committees, Professional Organizations

  • Member, World Molecular Imaging Society (2013 - Present)
  • Member, European Society of Molecular Imaging (2014 - Present)
  • Member, ASCO (2014 - Present)
  • Member, AACR (2014 - Present)

Professional Education

  • Residency, Charité University Medicine Berlin, Germany, Gastroenterology, Oncology (2010)
  • Residency, Charité University Medicine Berlin, Germany, Gerneral, Visceral, Vascular and Thoracic Surgery (2007)
  • Doctor of Medicine, Humboldt Universitat Zu Berlin (2006)

Stanford Advisors

Research & Scholarship


  • Development of new Imaging Tools in Neoplasia of the GI-Tract, Stanford University (October 1, 2012 - Present)

    Modern anti-cancer therapies have extended the survival times for many cancer patients but there is still improvements to be made as cancer mortality rates have, except for a few types of cancer, remained consistently high over the last five decades. By identifying highly sensitive imaging probes for the detection of cancer and its pre-steps we will improve outcomes for patients with the cancer through early detection, guided resection and thereby contribute to the reduction of the morbidity and mortality due to this malignant disease. In future those tools could work as well a therapeutics, which would open a new field - THERANOSTIC.


    350 Campus Drive, Stanford, USA

  • Anti-Angiogenic Drugs in the Treatment of Colon Cancer and Osteosarcoma, Charité University Medicine Berlin, Germany (February 1, 2007 - September 30, 2012)

    Anti-angiogenic drugs opened a new field in anti-cancer therapy. There mechanism is unique and in contrast to classic chemotherapeutic drugs well-tolerated. The well known anti-septic drug Taurolidine as well Emodin were tested on several completely different cancer entities such as colon cancer, melanoma and osteosarcoma in vitro and in vivo.


    Augustenburger Platz 1, Berlin, Germany


Journal Articles

  • Atherosclerotic Plaque Targeting Mechanism of Long-Circulating Nanoparticles Established by Multimodal Imaging ACS NANO Lobatto, M. E., Calcagno, C., Millon, A., Senders, M. L., Fay, F., Robson, P. M., Ramachandran, S., Binderup, T., Paridaans, M. P., Sensarn, S., Rogalla, S., Gordon, R. E., Cardoso, L., Storm, G., Metselaar, J. M., Contag, C. H., Stroes, E. S., Fayad, Z. A., Mulder, W. J. 2015; 9 (2): 1837-1847


    Atherosclerosis is a major cause of global morbidity and mortality that could benefit from novel targeted therapeutics. Recent studies have shown efficient and local drug delivery with nanoparticles, although the nanoparticle targeting mechanism for atherosclerosis has not yet been fully elucidated. Here we used in vivo and ex vivo multimodal imaging to examine permeability of the vessel wall and atherosclerotic plaque accumulation of fluorescently labeled liposomal nanoparticles in a rabbit model. We found a strong correlation between permeability as established by in vivo dynamic contrast enhanced magnetic resonance imaging and nanoparticle plaque accumulation with subsequent nanoparticle distribution throughout the vessel wall. These key observations will enable the development of nanotherapeutic strategies for atherosclerosis.

    View details for DOI 10.1021/nn506750r

    View details for Web of Science ID 000349940500080

    View details for PubMedID 25619964

Stanford Medicine Resources: